CHEMISTRY JOURNAL OF MOLDOVA. General, Industrial and Ecological Chemistry. 2025, 20(1), 100-105
ISSN (p) 1857-1727 ISSN (e) 2345-1688
http://cjm.ichem.md
https://doi.org/10.19261/cjm.2025.1337

MOLECULAR DOCKING STUDY OF SOME ACTIVE PRINCIPLES FROM *SILYBUM MARIANUM*, *CHELIDONIUM MAJUS*, *GINKGO BILOBA*, *GELSEMIUM SEMPERVIRENS*, *ARTEMISIA ANNUA*, AND *TARAXACUM OFFICINALE*

Daniel Cord [a], Mirela Claudia Rimbu [a,*], Cristiana Tanase [b], Cristina Tablet [c], Gheorghe Duca [d]

[a] *Medical Doctoral School, Titu Maiorescu University, 22, Dambovnicului str. Sector 4, Bucharest 040317, Romania*
[b] *Victor Babes National Institute of Pathology, 99-101, Splaiul Independentei, Sector 5, Bucharest 050096, Romania*
[c] *Faculty of Pharmacy, Titu Maiorescu University, 16, Gheorghe Sincai blvd., Bucharest 040314, Romania*
[d] *Institute of Chemistry, Moldova State University, 3, Academiei str., Chisinau MD-2028, Republic of Moldova*
[*] *e-mail: mirela.rimbu@prof.utm.ro*

Abstract. In this study, it was investigated by molecular docking, the interaction of fourteen natural compounds (artemisinin, bilobalide, bilobetin, chelerythrine, chelidonin, epicatechin, gelsemic acid, ginkgolide A, isosilybin, silicristin, silybin, taraxacin, taraxacoside, and taraxinic acid) from *Silbum marianum*, *Chelidonium majus*, *Ginkgo biloba*, *Gelsemium sempervirens*, *Artemisia annua*, and *Taraxacum officinale* with three cancer-related GPCRs: the apelin receptor, the *β*2-adrenoceptor, and the A2B adenosine receptor. QuickVina2 was used to determine the binding affinities and identify the nature of the strongest interactions. Several compounds (bilobetin, isosilybin, chelidonin, silicristin, and artemisinin) showed high binding affinities and interactions with key residues responsible for the receptor activity. These results highlight the potential of phytochemicals in modulating the activity of GPCRs and may form the basis for further experimental validation.

Keywords: natural compound, molecular docking, apelin receptor, *β*2-adrenoceptor, A2B adenosine receptor.

Received: 30 May 2025/ Revised final: 25 June 2025/ Accepted: 26 June 2025